Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK8 | P45983 | 5/20 | 0.34 |
| ▸ | MAPK9 | P45984 | 5/20 | 0.34 |
| ▸ | MAPK10 | P53779 | 2/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | PDE5A | O76074 | 1/20 | 0.31 |
| ▸ | PER2 | O15055 | 2/20 | 0.31 |
| ▸ | CRY1 | Q16526 | 2/20 | 0.31 |
| ▸ | CRY2 | Q49AN0 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23915534 | 0.87 | PTGDR2 (0.39) | MAPK8MAPK9MAPK10 | |
| SCHEMBL23913695 | 0.86 | DGAT1 (0.36) | MAPK8MAPK9MAPK10ATMPDE5A | |
| SCHEMBL23915023 | 0.85 | ATM (0.33) | MAPK8MAPK9MAPK10ATM | |
| SCHEMBL23914648 | 0.85 | MAPK8 (0.36) | MAPK8MAPK9MAPK10ATM | |
| SCHEMBL23914489 | 0.85 | SLC16A3 (0.33) | — | |
| SCHEMBL23915532 | 0.76 | CMA1 (0.32) | — | |
| SCHEMBL23915533 | 0.73 | AKR1B1 (0.39) | — | |
| SCHEMBL23915000 | 0.72 | DGAT1 (0.36) | ATMPDE5A | |
| SCHEMBL23914490 | 0.71 | MAPT (0.44) | — | |
| SCHEMBL23908827 | 0.70 | NPC1 (0.43) | PDE5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210315893-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF FIBROSIS | GILEAD SCIENCES, INC. | 2021-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210315893-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF FIBROSIS | S1PR1, S1PR3, S1PR2 | MAPK8 4275/4885MAPK9 3972/4885MAPK10 3337/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.